Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAS41007 vs Solaraze in Actinic Keratosis
NCT00991861Phase 2Completed
- Sponsor
- Almirall
- Start
- Aug 2009
- Primary completion
- Feb 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of diclofenac in actinic keratosis (AK) (3 arms), sponsored by Almirall. Primary endpoints: Histological clearance of one pre-selected target lesion at Day 120 and Complete clinical clearance of all target lesions in the treatment areas at Day 120. Started Aug 2009; status: completed.
02
Drugs
diclofenac
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT00991861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00991861.